FTC approves settlement with Akorn over Hi-Tech Pharmacal acquisition The Federal Trade Commission has approved a final order settling charges that Akorn Enterprises’ (AKRX) $640M acquisition of Hi-Tech Pharmacal was anticompetitive and would lead to higher prices for consumers in several current and future generic drug markets. The final order settling the FTC’s charges requires the parties to sell either Akorn’s or Hi-Tech’s rights and assets to each of five drug products to Watson Laboratories (ACT) and required Akorn to assign Watson its contract for making a currently available branded and generic topical anesthetic cream within 10 days after the deal is completed. Reference Link
News For AKRX;ACT From The Last 14 Days
Check below for free stories on AKRX;ACT the last two weeks.